ReviewClinical pharmacology and therapeutics2012
Autoimmunity and Graves' disease.
Review in Clinical pharmacology and therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ diseaseTurkish journal of medical sciences · 2019Trial
- TNFα drives disease-specific chemokine networks and orbital tissue remodeling in a preclinical model of thyroid eye disease.European thyroid journal · 2026Article
- Immunomodulatory Effects ofNutrients · 2025Article
- Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves' Orbitopathy.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023Article
- Is there an association between endometriosis and thyroid autoimmunity?Revista da Associacao Medica Brasileira (1992) · 2023Observational
- Proposing a surgical algorithm for graduated orbital decompression in patients with Graves' orbitopathy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Article
- Rare presentation of Graves' disease with myalgia: A case report.Clinical case reports · 2021Article
- Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review).Cancers · 2021Article
- The Molecular Function and Clinical Role of Thyroid Stimulating Hormone Receptor in Cancer Cells.Cells · 2020Review
- Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy.Eye (London, England) · 2019Article
- Therapeutic Effect ofEvidence-based complementary and alternative medicine : eCAM · 2019Article
- The influence of orbital decompression on objective nasal function in patients with graves' orbitopathy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2018Article
- Thyroid testing in acutely ill patients may be an expensive distraction.Biochemia medica · 2017Review
- STAT6 deficiency ameliorates Graves' disease severity by suppressing thyroid epithelial cell hyperplasia.Cell death & disease · 2016Article
- Graves Disease Is Associated With Endometriosis: A 3-Year Population-Based Cross-Sectional Study.Medicine · 2016Observational
- Rituximab in the Treatment of Thyroid Eye Disease: A Review.Neuro-ophthalmology (Aeolus Press) · 2015Review
- Discovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone Receptors.Frontiers in endocrinology · 2015Review
- Proteomic analysis of the differences in orbital protein expression in thyroid orbitopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2013Article
- Novel insights on thyroid-stimulating hormone receptor signal transduction.Endocrine reviews · 2013Review
- A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.The Journal of clinical endocrinology and metabolism · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Current treatment options for Graves' hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.